Merck, Mayo Clinic forge AI powerhouse to accelerate drug discovery

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

GSK’s Exdensur wins EU nod for severe asthma

The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen

Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI

Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care

Catalent and S.Biomedics join forces to advance groundbreaking Parkinson’s therapy

TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform

European Commission greenlights higher-dose Wegovy for obese adults

Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose

ExCellThera’s Zemcelpro scores big in Germany, paving way for early hospital access

The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission

Scinai acquires Recipharm Israel to expand global reach

This transaction fundamentally strengthens Scinai's CDMO platform

Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program

A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula

QCIL to build 350+ bed state-of-the-art CARE Hospital in Nagpur